---
reference_id: "PMID:39988443"
title: "[A Case Report of Lung Adenocarcinoma with EGFR G719A Mutation  and LMNA-NTRK1 Fusion]."
authors:
- Song S
- Yang Y
- Luo W
- Liang Y
- Li Q
- Zhuo T
- Xiong W
- Huang J
journal: Zhongguo Fei Ai Za Zhi
year: '2025'
doi: 10.3779/j.issn.1009-3419.2025.106.03
content_type: abstract_only
---

# [A Case Report of Lung Adenocarcinoma with EGFR G719A Mutation  and LMNA-NTRK1 Fusion].
**Authors:** Song S, Yang Y, Luo W, Liang Y, Li Q, Zhuo T, Xiong W, Huang J
**Journal:** Zhongguo Fei Ai Za Zhi (2025)
**DOI:** [10.3779/j.issn.1009-3419.2025.106.03](https://doi.org/10.3779/j.issn.1009-3419.2025.106.03)

## Content

1. Zhongguo Fei Ai Za Zhi. 2025 Jan 20;28(1):75-80. doi: 
10.3779/j.issn.1009-3419.2025.106.03.

[A Case Report of Lung Adenocarcinoma with EGFR G719A Mutation  and LMNA-NTRK1 
Fusion].

[Article in Chinese; Abstract available in Chinese from the publisher]

Song S(1), Yang Y(2), Luo W(2), Liang Y(3), Li Q(2), Zhuo T(2), Xiong W(2), 
Huang J(1)(2).

Author information:
(1)Department of Pathological Diagnosis and Research Center, the Affiliated 
Hospital of Guangdong Medical University, Zhanjiang 524001, China.
(2)Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou 510730, China.
(3)Department of Pathology,  Maternal and Child Health Hospital of Zhanjiang 
City, Zhanjiang 524000, China.

Fusion variations of neurotrophic receptor tyrosine kinase (NTRK) are oncogenic 
drivers in various solid tumors such as breast cancer, salivary gland carcinoma, 
infant fibrosarcoma, etc. Gene rearrangements involving NTRK1/2/3 lead to 
constitutive activation of the tropomyosin receptor kinase (TRK) domain, and the 
expressed fusion proteins drive tumor growth and survival. NTRK fusions are 
estimated to occur at a frequency of approximately 0.1% to 1% in non-small cell 
lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) mutations are 
prevalent in NSCLC, but the frequency of EGFR G719A mutation is relatively low 
(about 2%), and EGFR mutations are typically mutually exclusive with NTRK fusion 
variants. The study presented the first documented case of lung adenocarcinoma 
harboring both EGFR G719A mutation and LMNA-NTRK1 fusion. A review of the 
literature was conducted to elucidate the role of NTRK fusion mutations in NSCLC 
and their relationship with EGFR mutations, aiming to enhance the understanding 
of NTRK fusion mutations in NSCLC. .

Publisher: 【中文题目：EGFR G719A突变合并LMNA-NTRK1 融合变异的肺腺癌1例病例报道】 
【中文摘要：神经营养受体酪氨酸激酶（neurotrophic receptor tyrosine kinase, 
NTRK）的融合变异是多种成人和儿科恶性实体瘤的致癌驱动因素，如乳腺癌、唾液腺癌以及婴儿纤维肉瘤等。NTRK1/2/3的基因重排导致原肌球蛋白受体激酶（tropomyosin 
receptor kinase, TRK）结构域的组成型激活，表达的融合蛋白驱动肿瘤生长和存活。在非小细胞肺癌（non-small cell lung 
cancer, NSCLC）中，NTRK融合发生的频率为0.1%-1%。表皮生长因子受体（epidermal growth factor receptor, 
EGFR）在NSCLC中为常见突变，但EGFR 
G719A突变发生频率较低（约2%），且EGFR突变通常和NTRK融合变异互斥。本文首次报道1例原发性肺腺癌组织中同时伴有EGFR 
G719A突变和LMNA-NTRK1融合变异的罕见病例，并通过文献复习探讨NTRK融合变异在NSCLC中的作用以及与EGFR突变之间的关系，以提高对NTRK融合变异NSCLC的认识。 】 
【中文关键词：肺肿瘤；NSCLC；EGFR突变；NTRK融合】.

DOI: 10.3779/j.issn.1009-3419.2025.106.03
PMCID: PMC11848618
PMID: 39988443 [Indexed for MEDLINE]

Conflict of interest statement: Competing interests: The authors declare that 
there are no conflicts of interest present.